Henry F. Edelhauser served on the faculty at the Medical College of Wisconsin (1966 - 1989) as an assistant, associate and then full professor. In 1989 he became the First Professor of Ophthalmology and Director of Ophthalmic Research at Emory University. He has served as president of the Association for Research in Vision and Ophthalmology (ARVO), received the honor and senior achievement award from the American Academy of Ophthalmology. In 1999 he was awarded the Castroviejo Medal and the Alcon Research Award. His research interests include surgical pharmacology, corneal physiology, drug delivery and ocular toxicology. Dr. Edelhauser presented a keynote lecture at the 55th Congress of Clinical Ophthalmology of Japan entitled “Cataract and Refractive Surgery: The Effect on the Corneal Endothelium.”
GTC’s 4th Ocular Diseases and Drug Discovery Conference will bring together a 50-50 mix of academic and high-level industry experts from leading affiliations to discuss and collaborate on the latest research and discovery, safety assessment, and development of drugs for combating and curing age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, uveitis and other eye diseases. Leading scientists and researchers include key experts such as M. (Ken) Kengatharan, Barbara Wirostko, David Woodward, Henry F. Edelhauser, Ken Mandell, Bala Ambati, etc. The last annual conference was well attended with representation from key R&D professionals from GSK, Pfizer, B&L, Allergan and Alcon and this year is showing promise of being even bigger and better.
This conference is part of the Targets and Strategies in Drug Discovery Summit and runs concurrently with three other tracks:
1) 3rd Cancer Targets and Therapeutics
2) Oncology Partnering & Deal-Making Conference
3) 2nd Ubiquitin Research and Drug Discovery
For more information, please visit www.gtcbio.com